Skip to content
Oncology Research Hub

Portland, Oregon

Cancer clinical trials in Portland, OR

207 cancer studies are recruiting participants at sites in Portland as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Portland at a glance

  • 207 studies are recruiting at a site in Portland.
  • By phase: Early Phase 1 (2), Phase 1 (23), Phase 1/2 (30), Phase 2 (53), Phase 2/3 (6), Phase 3 (61), Phase 4 (3), No phase (7), Observational (22). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (105), university, hospital or other (83), government (19).
  • By research area: Lung Cancer (57), Lymphoma (48), Breast Cancer (46), Prostate Cancer (29), Pancreatic Cancer (19), Melanoma (8).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Portland

Basic details from each study's public record (the 30 most recently updated of 207). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Kaiser Permanente Northwest · Oregon Health and Science University
    Registry record
    NCT03418961 · updated
  2. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Oregon Health and Science University · Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT05564377 · updated
  3. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Legacy Good Samaritan Hospital and Medical Center · Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT06058377 · updated
  4. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Providence Cancer Institute Franz Clinic
    Registry record
    NCT06638307 · updated
  5. Post-Marketing Study for Early-Stage Low-Risk Breast Cancer Treatment Using ProSense® Cryoablation (ChoICE Trial)

    • No phase
    • Ages 70 and older
    • All sexes
    Sponsor
    IceCure Medical Ltd.
    Study site
    Legacy Medical Group-Surgical Oncology at Good Samaritan
    Registry record
    NCT07629206 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Lung cancer studies recruiting in Portland

  1. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novelty Nobility, Inc.
    Study site
    Oregon Health & Science University
    Registry record
    NCT06805825 · updated
  2. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study sites
    Kaiser Permanente Interstate Medical Office Central · Providence Portland Medical Center
    Registry record
    NCT07063745 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kaiser Permanente Northwest · Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT04267848 · updated
  4. Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

    • Observational
    • All ages
    • All sexes
    Sponsor
    Lung Cancer Mutation Consortium
    Study site
    Providence Portland
    Registry record
    NCT04712877 · updated
  5. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Oregon Health and Science University · Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT06498635 · updated
  6. Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    SystImmune Inc.
    Study site
    Providence Cancer Institute
    Registry record
    NCT07080242 · updated
  7. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study sites
    Oregon Health and Science University · Providence Cancer Institute Franz Clinic · Providence St. Vincent Medical Center
    Registry record
    NCT07100080 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Prostate cancer studies recruiting in Portland

  1. Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    VA Portland Health Care System, Portland, OR
    Registry record
    NCT04038502 · updated
  2. High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    VA Office of Research and Development
    Study site
    VA Portland Health Care System, Portland, OR
    Registry record
    NCT05011383 · updated
  3. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Oregon Health and Science University · Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT04423211 · updated
  4. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    VA Portland Health Care System ( Site 0058)
    Registry record
    NCT06136624 · updated
  5. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Oregon Health and Science University · Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Melanoma studies recruiting in Portland

  1. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT05136196 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Portland, OR on ClinicalTrials.gov.

Lymphoma studies recruiting in Portland

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT06724237 · updated
  2. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study sites
    Providence Portland Medical Center · Providence St. Vincent Medical Center
    Registry record
    NCT06806033 · updated
  3. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Kaiser Permanente Interstate Medical Office - Central ( Site 0181)
    Registry record
    NCT06717347 · updated
  4. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Providence Oncology and Hematology Clinic Westside ( Site 0179) · Providence Portland Medical Center ( Site 0120)
    Registry record
    NCT06890884 · updated
  5. Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT03739814 · updated
  6. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT04269902 · updated
  7. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Legacy Emanuel Children's Hospital · Oregon Health and Science University
    Registry record
    NCT04546399 · updated
  8. Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT04840602 · updated
  9. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Legacy Emanuel Children's Hospital · Oregon Health and Science University · Providence Portland Medical Center
    Registry record
    NCT05675410 · updated
  10. TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    • Phase 1/2
    • Up to age 1
    • All sexes
    Sponsor
    Tanja Andrea Gruber
    Study site
    Doernbecher Children's Hospital
    Registry record
    NCT05848687 · updated
  11. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Kaiser Permanente Northwest · Oregon Health and Science University · Providence Portland Medical Center
    Registry record
    NCT06337318 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Portland, OR on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Portland

  1. APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Oregon Health and Science University · Providence Portland Medical Center · Providence Saint Vincent Medical Center
    Registry record
    NCT04858334 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Portland, OR on ClinicalTrials.gov.

Ask about studies near Portland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call